A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, First-in-Human, Phase 1/2, multicenter study to evaluate the safety
and efficacy of a single dose of AVB-001. AVB-001 is an encapsulated cell product engineered
to produce native human interleukin-2 (hIL-2). It is delivered intraperitoneally (IP) to
patients with high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian
tube.